https://doi.org/10.1200/jco.2018.78.9909
F
Francisco J. Esteva
Northwell Health(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
455
Papers
27.9K
Citations
80
h-index
212
i10-index
Francisco J. Esteva is an academic researcher from Northwell Health. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology & Breast Cancer Treatment Studies. The author has an h-index of 80, co-authored 387 publications.
ORCID: 0000-0003-2437-3920Papers by this author
worksPhase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
2018 · Journal of Clinical Oncology · 1,086 citations
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
2006 · Nature Clinical Practice Oncology · 913 citations
https://doi.org/10.1038/ncponc0509
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
2019 · New England Journal of Medicine · 821 citations
https://doi.org/10.1056/nejmoa1911149
Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells
2005 · Cancer Research · 795 citations
https://doi.org/10.1158/0008-5472.can-04-3841
Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer
2002 · Journal of Clinical Oncology · 570 citations
https://doi.org/10.1200/jco.2002.07.058
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
2011 · Nature Medicine · 514 citations
https://doi.org/10.1038/nm.2309
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat